Health Care [ 12/12 ] | Biotechnology [ 64/73 ]
NASDAQ | Common Stock
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States.
Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy.
It also develops VXX-401, that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313, which is in Phase 1 clinical trial targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial.
It has a collaboration agreement with the University of Florida, University of Central Florida, and the University of Southampton.
The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 1, 25 | -0.09 Decreased by -0.11% | -0.08 Decreased by -12.50% |
| Nov 29, 24 | 0.00 Increased by +100.00% | -0.10 Increased by +100.00% |
| Aug 8, 24 | 0.00 Increased by +100.00% | -0.10 Increased by +100.00% |
| May 7, 24 | 0.00 Increased by +100.00% | -0.10 Increased by +100.00% |
| Mar 27, 24 | -0.09 Increased by +43.81% | -0.10 Increased by +10.10% |
| Nov 8, 23 | -0.10 Increased by +33.33% | -0.12 Increased by +16.67% |
| Aug 9, 23 | -0.11 Increased by +21.43% | -0.15 Increased by +26.67% |
| May 9, 23 | -0.15 Increased by 0.00% | -0.16 Increased by +6.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | N/A Decreased by N/A% | -11.39 M Increased by +38.16% | - - |
| Dec 31, 23 | 0.00 Decreased by N/A% | -11.39 M Increased by +44.35% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -13.14 M Increased by +31.72% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -13.98 M Increased by +19.11% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -18.42 M Decreased by -0.87% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Increased by +100.00% | -20.47 M Increased by +57.52% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -19.25 M Increased by +36.65% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -17.28 M Increased by +35.79% | Decreased by N/A% Decreased by N/A% |